Diagnostics antibodies and antigens for Chronic atrophic gastritis (CAG)

Chronic atrophic gastritis (CAG) with intestinal metaplasia is recognized to be a precancerous lesion that can evolve toward low- and high-grade intraepithelial lesions and gastric cancer. CAG is characterized by loss of gastric glands and can be evaluated endoscopically, histologically and serologically. Therefore, its early detection is a priority in preventing gastric cancer. Hence, biomarkers such as Gastrin-17 (G-17) and so on have been developed to detect the chronic atrophic gastritis at an early stage to significantly reduce the gastric cancer.

GENEMEDI developed the Gastrin-17 (G-17) antigens and antibodies for the diagnosis of chronic atrophic gastritis based on ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.

Genemedi supplies antibodies and antigens for Chronic atrophic gastritis (CAG) testing for a wide selection of choices (please see below).

G17

Gastrin 17 (G17)

Cat No.	Antibody/Antigen Name	Expression platform	Isotypes	Bioactivity validation	Order
GMP-SMT-G17-Ag; GMP-SMT-G17-Ab	Antigen: BSA-Gastrin 17 (G17); Antibody: Anti-Gastrin 17 (G17) mouse monoclonal antibody(mAb)	Antigen: Synthetic; Antibody:  CHO	Antigen: NA; Antibody: Mouse IgG	Antigen: Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT Antibody: human Gastrin 17 (G17) binding, Competitive immunoassay validation (Competitive ELISA) in G17 level test and Chronic atrophic gastritis (CAG) evaluation.